October 17, 2016 / 1:22 PM / 10 months ago

BRIEF-FDA staff raise concerns about Allergan, Serenity Pharma urinary drug

Oct 17 (Reuters) - U.S. FDA -

* FDA staff says 1.5 mcg dose of Allergan's Nocturia drug met efficacy criteria, but clinical meaningfulness of dose is unclear compared to placebo

* FDA staff says of five deaths in clinical trials of drug, the role of drug cannot be definitively ruled out for two deaths

* FDA staff says the proposed dosing regimen for drug has not been studied in any clinical trials Source text - (bit.ly/2dIxcrs)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below